GlaxoSmithKline (CAI:BIOC) Beginning Cash Position: E£494 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Beginning Cash Position?

GlaxoSmithKline CAI:BIOC -7.19% Beginning Cash Position is E£494 Mil as of Sep. 2016.

GlaxoSmithKline's Beginning Cash Position for the quarter that ended in Sep. 2016 was E£494 Mil.

GlaxoSmithKline's quarterly Beginning Cash Position declined from Mar. 2016 (E£645 Mil) to Jun. 2016 (E£521 Mil) and declined from Jun. 2016 (E£521 Mil) to Sep. 2016 (E£494 Mil).

GlaxoSmithKline's annual Beginning Cash Position increased from Dec. 2013 (E£116 Mil) to Dec. 2014 (E£311 Mil) and increased from Dec. 2014 (E£311 Mil) to Dec. 2015 (E£514 Mil).

GlaxoSmithKline Beginning Cash Position Related Terms

GlaxoSmithKline Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Beginning Cash Position Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Beginning Cash Position
45.01 116.19 310.96 514.12

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 458.55 528.23 645.43 521.13 494.37

GlaxoSmithKline Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of E£494 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Beginning Cash Position of E£494 Mil as of Sep. 2016. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Beginning Cash Position too high?
GlaxoSmithKline's current Beginning Cash Position is E£494 Mil.
How does GlaxoSmithKline's Beginning Cash Position compare to PRPH?
GlaxoSmithKline's Beginning Cash Position of E£494 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Beginning Cash Position is E£494 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Beginning Cash Position of E£494 Mil. The current Beginning Cash Position is E£494 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Beginning Cash Position is E£494 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.